Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)
Condition: COVID-19 Interventions: Biological: GAMUNEX-C; Drug: Standard Medical Treatment Sponsor: Grifols Therapeutics LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 21, 2020 Category: Research Source Type: clinical trials
Pharmacokinetics, Safety and Tolerability, and Efficacy Evaluation of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)
Condition: Primary Immunodeficiency Diseases (PID) Interventions: Biological: Immune Globulin Intravenous (IGIV); Biological: Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%) Sponsor: Baxalta now part of Shire Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2020 Category: Research Source Type: clinical trials
